Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kymera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 5 insiders, $33.5M in total
- Insiders trading
- 5
- Net value
- −$33.5M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kymera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Adams Brian | Chief Legal Officer | 50,254 | Sep 4, 2026 | 2 |
| Rooney Terence | Chief Medical Officer | 38,000 | Jul 27, 2026 | 1 |
| Mainolfi Nello | Chief Executive Officer | 666,568 | Jul 7, 2026 | 10 |
| Jacobs Bruce N. | Chief Financial Officer | 244,883 | Jul 2, 2026 | 4 |
| Goodman Noah | Chief Business Officer | 47,179 | Jul 2, 2026 | 6 |
| Booth Bruce | Director | 462,856Indirect | Jul 2, 2026 | 12 |
| Biotechnology Value Fund L P | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Partners L P | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Inc | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Biotechnology Value Fund II LP | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Lampert Mark N | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Biotechnology Value Trading Fund OS LP | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Partners OS Ltd. | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF I GP LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF II GP LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF GP Holdings LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Baker Julian | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Felix | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Bros. Advisors LP | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| 667, L.P. | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Maraganore John | Director | – | Jun 25, 2026 | 1 |
| Sandor Victor | Director | – | Jun 25, 2026 | 1 |
| Albers Jeffrey W. | Director | 0 | Jun 25, 2026 | 3 |
| Esposito Pamela | Director | 1,000 | Jun 25, 2026 | 6 |
| Ridloff Elena | Director | 0 | Jun 25, 2026 | 3 |
| Hrustanovic Gorjan | Director | – | Jun 25, 2026 | 1 |
| Chadwick Jeremy G | Chief Operating Officer | 44,018 | May 27, 2026 | 7 |
| Gollob Jared | Chief Medical Officer | 117,134 | Mar 4, 2026 | 4 |
| Chiniara Ellen | Chief Legal Officer | 80,085 | Mar 3, 2025 | 0 |
| Morgan Leigh | Director | – | Jun 20, 2024 | 0 |
| Horobin Joanna | Director | 0 | Jun 7, 2024 | 0 |
| Atlas Venture Fund X, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates X, LLC | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates X, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Caughey Elaine | Chief Business Officer | 18,986 | Mar 3, 2023 | 0 |
| Nicholson Donald William | Director | – | Jun 16, 2022 | 0 |
| Chesworth Richard | Chief Scientific Officer | 0 | Aug 27, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 (view filing) | Mar 31-Apr 1 | 1 day | Ridloff ElenaDirector | SSale | −12.0K | $85.39 | −$1.02M | −100.0%0 after | 3 lots10b5-1 |
| Apr 10, 2026 (view filing) | Apr 9-10 | 1 day | Goodman NoahChief Business Officer | SSale | −10.3K | $87.47 | −$897.8K | −16.6%51.5K after | 4 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14-15 | 2 days | Chadwick Jeremy GChief Operating Officer | SSale | −6.55K | $90.00 | −$589.6K | −9.7%61.2K after | 2 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14 | 2 days | Goodman NoahChief Business Officer | SSale | −1.35K | $90.00 | −$121.2K | −2.6%50.2K after | 10b5-1 |
| Apr 16, 2026 (view filing) | Apr 14-15 | 2 days | Booth BruceDirector | SSale | −6.36K | $89.96 | −$572.1K | −100.0%0 after | 2 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 15 | 1 day | Booth BruceDirector | SSale | −3.13K | $90.10 | −$282.5K | −0.5%675.0K after | 2 lots10b5-1 |
| Apr 24, 2026 (view filing) | Apr 22 | 2 days | Chadwick Jeremy GChief Operating Officer | SSale | −300 | $90.00 | −$27.0K | −0.5%61.2K after | 10b5-1 |
| Apr 24, 2026 (view filing) | Apr 22 | 2 days | Booth BruceDirector | SSale | −5.90K | $89.96 | −$530.8K | −100.0%0 after | 10b5-1 |
| Apr 24, 2026 (view filing) | Apr 22 | 2 days | Booth BruceDirector | SSale | −100 | $90.08 | −$9.01K | 0.0%674.9K after | 2 lots10b5-1 |
| Apr 29, 2026 (view filing) | Apr 29 | Same day | Mainolfi NelloChief Executive Officer | SSale | −30.0K | $81.18 | −$2.44M | −4.3%666.2K after | 3 lots10b5-1 |
| May 11, 2026 (view filing) | May 11 | Same day | Ridloff ElenaDirector | SSale | −3.00K | $87.00 | −$261.0K | −100.0%0 after | 10b5-1 |
| May 27, 2026 (view filing) | May 26-27 | 1 day | Chadwick Jeremy GChief Operating Officer | SSale | −17.2K | $79.92 | −$1.37M | −28.1%44.0K after | 7 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 22 | Same day | Goodman NoahChief Business Officer | SSale | −2.50K | $99.00 | −$247.5K | −4.7%50.2K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Booth BruceDirector | SSale | −11.7K | $89.98 | −$1.06M | −100.0%0 after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17-22 | 5 days | Booth BruceDirector | SSale | −466.5K | $94.84 | −$44.2M | −43.0%617.7K after | 28 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 22 | Same day | Booth BruceDirector | SSale | −31.8K | $103.75 | −$3.30M | −4.9%613.8K after | 4 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 25 | Same day | Goodman NoahChief Business Officer | SSale | −5.00K | $114.00 | −$570.0K | −9.1%50.2K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23-25 | 2 days | Booth BruceDirector | SSale | −398.8K | $110.31 | −$44.0M | −41.4%564.7K after | 30 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 25 | Same day | Booth BruceDirector | SSale | −285.7K | $121.86 | −$34.8M | −35.0%529.7K after | 22 lots10b5-1 |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −1.58M | $106.50 | −$168.1M | −86.8%240.1K after | 3 lots |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −51.9K | $106.50 | −$5.52M | −39.7%78.8K after | |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Booth BruceDirector | SSale | −513.2K | $110.01 | −$56.5M | −52.4%466.1K after | 30 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Booth BruceDirector | SSale | −31.3K | $109.48 | −$3.42M | −6.3%461.8K after | 8 lots10b5-1 |
| Jul 2, 2026 (view filing)5:39 PM ET | Jun 29 | 3 days | Booth BruceDirector | SSale | −76.7K | $108.05 | −$8.28M | −14.2%462.9K after | Amended14 lots10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Mainolfi NelloChief Executive Officer | SSale | −80.0K | $115.29 | −$9.22M | −10.7%666.6K after | 5 lots10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Goodman NoahChief Business Officer | SSale | −3.39K | $114.29 | −$387.3K | −6.7%47.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jun 30 | 2 days | Jacobs Bruce N.Chief Financial Officer | SSale | −77.1K | $114.96 | −$8.86M | −23.9%244.9K after | 8 lots10b5-1 |
| Jul 7, 2026 (view filing)8:00 PM ET | Jul 7 | Same day | Mainolfi NelloChief Executive Officer | SSale | −50.0K | $119.00 | −$5.95M | −7.0%666.6K after | 10b5-1 |
| Sep 4, 2026 (view filing)6:00 PM ET | Sep 4 | Same day | Adams BrianChief Legal Officer | SSale | −6.37K | $116.83 | −$744.3K | −11.3%50.3K after | 3 lots |